Results 61 to 70 of about 18,729 (264)

SPARCL1 and NT‐proBNP as biomarkers of right ventricular‐to‐pulmonary artery uncoupling in pulmonary hypertension

ESC Heart Failure, Volume 12, Issue 2, Page 1416-1426, April 2025.
Abstract Aims SPARCL1 was recently identified as a biomarker of right ventricular (RV) maladaptation in patients with pulmonary hypertension (PH), and N‐terminal pro‐brain natriuretic protein (NT‐proBNP) is an established biomarker of RV failure in PH. The present study investigated whether NT‐proBNP and SPARCL1 concentrations are associated with load ...
Oliver Dörr, Stanislav Keranov, Paulina van Wickern, Holger Nef, Christian Hamm, Pascal Bauer, Christian Troidl, Samuel Sossalla, Sandra Voss, Christoph Liebetrau, Manuel J. Richter, Henning Gall, Werner Seeger, Ardeschir Ghofrani, Athiththan Yogeswaran, Khodr Tello   +15 more
wiley   +1 more source

Long Term Administration of Endothelin Receptor Antagonist Improves Coronary Endothelial Function in Patients with Early Atherosclerosis

Circulation, 2010
Background— Endothelin (ET-1) is one of the most potent vasoconstrictors and plays a seminal role in the pathogenesis of atherosclerosis. The present study was designed to test the hypothesis that long-term treatment with an endothelin-A (ETA) receptor ...
M. Reriani, E. Raichlin, A. Prasad, V. Mathew, Geralyn M. Pumper, Rebecca E. Nelson, R. Lennon, C. Rihal, Lilach O. Lerman, A. Lerman   +9 more
semanticscholar   +1 more source

A review of sitaxsentan sodium in patients with pulmonary arterial hypertension

Vascular Health and Risk Management, 2007
Aaron B WaxmanDepartment of Internal Medicine, Pulmonary Critical Care Unit, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USAAbstract: Pulmonary arterial hypertension (PAH) is a life threatening, progressive condition which ...
Aaron B Waxman
doaj  

Predictive Biomarkers in Metastatic Colorectal Cancer Patients Treated With Bevacizumab: A Turkish Oncology Group (TOG) Study

International Journal of Cancer, EarlyView.
Bevacizumab added to systemic chemotherapy remains a cornerstone of metastatic colorectal cancer treatment, but its effectiveness is variable. Tumors can bypass the VEGF blockade by activating other pro‐angiogenic pathways, hampering the identification of predictive biomarkers.
Büsra Akay Hacan, Fatma Gizem Sonugür, Müge Öçal, Cansu Babahan, Samira Abgarmi, Ülkü Yalçıntaş Arslan, Mehmet Ali Şendur, Ahmet Demirkazık, Güngör Utkan, Hakan Akbulut   +9 more
wiley   +1 more source

Structural basis of antagonist selectivity in endothelin receptors

Cell Discovery
Endothelins and their receptors, ETA and ETB, play vital roles in maintaining vascular homeostasis. Therapeutically targeting endothelin receptors, particularly through ETA antagonists, has shown efficacy in treating pulmonary arterial hypertension (PAH)
Junyi Hou, Shenhui Liu, Xiaodan Zhang, Guowei Tu, Lijie Wu, Yijie Zhang, Hao Yang, Xiangcheng Li, Junlin Liu, Longquan Jiang, Qiwen Tan, Fang Bai, Zhijie Liu, Changhong Miao, Tian Hua, Zhe Luo   +15 more
doaj   +1 more source

Distinct ETA receptor binding mode of macitentan as determined by site directed mutagenesis. [PDF]

PLoS ONE, 2014
The competitive endothelin receptor antagonists (ERA) bosentan and ambrisentan, which have long been approved for the treatment of pulmonary arterial hypertension, are characterized by very short (1 min) occupancy half-lives at the ET(A) receptor.
John Gatfield, Celia Mueller Grandjean, Daniel Bur, Martin H Bolli, Oliver Nayler   +4 more
doaj   +1 more source

Maternal and perinatal outcomes of pregnant women with echocardiographically high probability of pulmonary arterial hypertension

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective This study aimed to describe maternal and perinatal outcomes among pregnant women with echocardiographically high probability of pulmonary arterial hypertension (PAH) managed at a quaternary center and to compare outcomes between women with and without cardiac complications (CC).
Laura Belmont‐Rojo, Rosa Hernandez‐Cruz, Ana Jimena Lopez‐Diaz, Diana Yazmin Copado‐Mendoza, Tirso Rubalcava‐Rubalcava, Mario Isaac Lumbreras‐Marquez, Maria Antonia Pijuan‐Domenech   +6 more
wiley   +1 more source

Insulin Resistance: An Update on Biochemical and Pathophysiological Mechanisms and Impact on Various Diseases

iNew Medicine, EarlyView.
ABSTRACT Insulin resistance is the biological phenomenon in which the human body's normal response to the metabolic hormone insulin is compromised. Insulin is a regulator of most of the essential metabolic steps in the body that control energy homoeostasis, so dysregulation leads to multiple diverse human diseases including, most prominently, Type 2 ...
Peter J. Little, Stefan Offermanns, Haaglim Cho, Zhiping Liu, Pinglian Yang, Qiaozhu Su, Henry Wade, Wah Yang, Danielle Kamato, Neale Cohen, Alex Bobik, Iqra Ilyas, Suowen Xu   +12 more
wiley   +1 more source

Aprocitentan (TRYVIO)

Amrita Journal of Medicine
Aprocitentan (TRYVIO), is the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with 3 combined antihypertensive class drugs.
Shalini Thomas
doaj   +1 more source

Taking Into Account Insulin Resistance With Associated Hyperinsulinemia to Counteract the Development of Acute and Chronic Cardiovascular Diseases

Chronic Diseases and Translational Medicine, EarlyView.
Serafino Fazio, Flora Affuso
wiley   +1 more source